Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer
1 Department of Surgery, University of Pennsylvania Perelman School of Medicine, Rena Rowen Breast Center, 3400 Civic Center Drive, Philadelphia 19104, PA, USA
2 Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
3 Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
4 Department of Pathology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
5 Rena Rowen Breast Center, Hospital of the University of Pennsylvania, Philadelphia, PA, USA